Abstract
TALA is a poly (ADP-ribose) polymerase inhibitor approved in the US, EU, and other countries for the treatment of deleterious/suspected deleterious gBRCA1/2mut HER2-negative ABC. While TALA treatment in the phase 3 EMBRACA trial (NCT01945775) benefited pts regardless of PP, greater improvements in clinical outcomes for TALA vs PCT (capecitabine, eribulin, gemcitabine, or vinorelbine) were seen for pts not treated with PP (PFS hazard ratio [95% CI] 0.76 [0.40–1.45], P = 0.41 for PP vs 0.52 [0.39–0.71], P < 0.0001 for no-PP subgroups).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
